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SUMMARY
Glial-cell-line-derived neurotrophic factor
(GDNF) stimulates the survival of dopaminergic
neurons. Little is known, however, about the
possible immune sequelae of GDNF exposure or
of exposure to other putative trophic factors. To
address these questions, pieces of mesencephalic
tissue, substantia nigra, from 15-day-old donor
embryos were transplanted into the anterior
chamber of the eye of adult male Sprague-
Dawley recipient rats. At 5-day intervals, an
aliquot (0.5 ttg) of GDNF, brain-derived neuro-
trophic factor (BDNF), neurotrophin-3 (NT-3),
or cytochrome-C (CC) was injected into the
anterior chamber of the eye of the recipients,
and the sizes of the transplants were measured.
GDNF increased transplant survival and
growth. On day 42, all rats were sacrificed, and
the grafts were evaluated by cresyl-violet
staining and by immunohistochemistry using
antibodies raised against neurofilament (NF),
tyrosine hydroxylase, or glial fibrillary acidic
protein (GFAP), as well as the following
monoclonai antibodies: OX-38 anti-CD4, OX-$
anti-CDS, OX-18 anti-MHC class I, OX-6 anti-
MHC class II, OX-42 anti-CDllb, R-73 anti-cz
and anti- T-cell receptor, and EDI raised
against monocytes/macrophages. BDNF-treated
grafts showed only weak immunoreactivity, and
even weaker reactions were seen in grafts
treated with NT-3, GDNF, or CC. No single
immune system marker was significantly
elevated in grafts from any treatment group. We
used OX-42 and EDI to study possible
alterations of microglial components. Ramified
microglial cells were found in GDNF-treated
grafts and to a lesser extent in NT-3 and BDNF-
treated grafts. EDl-labeled reactive microglial
components were found in NT-3- and BDNF-
treated grafts. Additionally, large and rounded
OX-42-positive phagocytic cells were found in
NT-3-treated grafts. Together with our previous
finding that GDNF treatment of spinal cord
transplants activates immune responses and
leads to microglial activation, our data
demonstrate that although treatment with
GDNF and to some degree with BDNF can
enhance immune responses to immunogenic
grafts, such as fetal spinal cord grafts, but the
trophic factors per se do not elicit any marked
response in non-immunogenic grafts like
substantia nigra.
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INTRODUCTION
Glial-cell-line-derived neurotrophic factor
(GDNF) shows trophic effects not only on ventral
mesencephalic dopaminergic neurons /4,6,11,18,
37,44,48/ but also on spinal cord motoneurons
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/30,54/, but little is known about the possible
immune sequelae of host and graft exposure to
GDNF or to other putative trophic factors. In
allogeneic but not syngeneic intraocular fetal spinal
cord transplants, GDNF upregulates the expression
ofmajor histocompatibility (MHC) loci antigens and
activates graft-derived microglial cells/40/. GDNF
mRNA in the cortex and hippocampus is
upregulated in such pathological conditions as
experimentally induced status epilepticus in the
hippocampus and striatum/38/.
GDNF is a member of the transforming growth
factor-13 (TGF-13) superfamily /24/ of proteins that
are produced and secreted by a variety of
immunocytes /52/. The TGF-13 proteins are well-
known immunomodulators having the following
immune functions: (a)inhibit the proliferation of
thymocytes, T-cells, B-cells, and natural killer (NK)
cells; (b) inhibit the generation of cytotoxic
macrophages; (d) inhibit IgG and IgM production;
(e) switch B-cells from IgG to IgA production; (f)
modulate the production of cytokines; and (g) serve
as chemoattractants for monocytes and neutrophils
/52/. TGF-13 proteins, however, have also been
reported to elicit strong immune responses
(reviewed in/10,15,28,50/).
Intraocular transplantation of central nervous
system (CNS) tissue provides a unique method for
examining the in vivo effects of trophic factors.
Such proteins can be selectively administered into
the anterior chamber, thus minimizing remote or
indirect drug effects/6,18,44,49/. For example, fetal
substantia nigra tissue grafted to the anterior
chamber of the eye responds to GDNF /44/. Of
particular relevance for immunological studies is
that allogeneic grafts, even when manifesting good
survival and growth, contain significant amounts of
immunoreactive elements. In addition, area-specific
differential immune responses are elicited aRer
grafting/39/.
In the study presented here, we used embryonic
substantia nigra transplants and an in oculo graft
model as appropriate targets for GDNF activity to
determine whether the TGF-13 superfamily trophic
molecule, in addition its stimulatory effects, might
induce or interact with immune elements. To
monitor the various elements of the immune system
after GDNF administration, we used monoclonal
antibodies (mAbs) raised against the following
T-cell, B-cell, or monocytehnacrophage cell-surface
antigens: rat CD4 (OX-38), rat CD8 (OX-8), rat
MHC class I (OX-18); rat MHC class II (OX-6).
MAb (OX-42) raised against rat CDllb identifies
cellular complement-receptor type 3 (CR3), which
is found on the surface of classical (ramified) and
ameboid and/or reactive microglial subtypes
/14,36,/45/. MAb ED-1, raised against rat mono-
cytes and macrophages, is a cytoplasmic marker of
macrophages or activated microglia or both/8/that
localizes only to cells of the monocytic lineage
/9,45/. We used allogeneic grafts to vary the basal
immune status of the CNS tissue. For purposes of
comparison, we tested other trophic factors from
the neurotrophin family, including brain-derived
neurotrophic factor (BDNF), which has survival-
promoting activity on substantia nigra/17,21/, and
neurotrophin-3 (NT-3), which influences immune
reactions in grafted CNS tissue/40/.
MATERIALS AND METHODS
Intraocular grafting procedures
Young adult male Sprague-Dawley rats (SD
rats, B & K, Sweden) weighing 150 g each were
used as recipients of intraocular grafts. Fetuses from
pregnant female rats were used as donors of
embryonic mesencephalic tissue grafts. On the 15th
embryonic-day (El5), pieces (1-3 mm Wide) of
substantia nigra were dissected out from the fetuses
and bilaterally grafted, under ether anesthesia, to the
anterior eye chamber of the eye of the adult hosts.
To prevent prolapse of the iris, the eyes were
pretreated with a drop of 1% atropine solution. The
grafts were placed on the anterior surface of the iris
through a small opening in the cornea as previously
described/29/. Every 5th day aer grafting (up to
day 40), the volume of each transplant was
estimated by stereomicroscopic observation,
measuring the longest diameter multiplied by the
diameter perpendicular to it. Every 5th day, each
eye was injected with 5 L of a solution containing
0.5 lag of one of the following factors: (a) GDNF
(100 g/mL), (b) cytochrome C (CC, 100 lag/mL),
(c) BDNF (100 lag/mL), (d) NT-3 (100 lag/mL)
/49/. Donor material from any one dam was equally
distributed among all treatment groups. The
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measured sizes of the gratis correlate well with the
actual weight ofthe grats at sacrifice/5/.
Immunohistochemistry
Forty-two days after transplantation, the host
animals were deeply anesthetized with sodium
pentobarbital (60 mg/kg, i.p.) and perfused via the
ascending aorta with 50 mL of calcium-free tyrode
solution (37 C) and then with 300 mL of ice-cold
fixative (4% paraformaldehyde in phosphate buffer).
Transplants attached to host irises were post-fixed
by immersion for 30-60 min in the same fixative,
rinsed in 10% sucrose, frozen, and then sectioned
on a cryostat at 14 lam. Sections at periodicities of 8
to 12 were processed for glial fibrillary acid protein
(GFAP, Sigma(R)) (1"100), neurofilament (NF, a
kind gift from Prof. Doris Dahl((1:400), and
tyrosine hydroxylase (TH, Pel Freeze(R)) immuno-
histochemistry (1:00), or stained for cresyl violet.
MAbs raised against rat CD4-clone OX-38, rat
CD8-clone OX-8, rat CDllb-clone OX-42, rat
MHC class I-clone OX-18, and rat ED-1 raised
against monocytes and macrophages were
purchased from Serotec(R); rat MHC class II-clone
OX-6 was obtained from Pharmingen(R). Primary
MAbs were diluted 1:1000, except for OX-42
(1:200) and ED-1 (1:300). All tissues were stored
for 48 hr at 4C in a humidified chamber. For
OX-38, 0X-8, 0X-42, and OX-18, the secondary
antibody was Fluorescein-linked rabbit anti-mouse
IgG. For GFAP, NF, and TH, Fluorescein-
isothiocyante (FITC)-labeled goat anti-rabbit IgG
’served as the second antibody /39,41/. For each
gra, a "total immunological score" was calculated
by a summation of the scores for CD4, CD8, MHC
classes I and II. Immunological scores were based
on cell counts as follows: scores of 0, 0.5, 1, 1.5, 2,
2.5, 3, 3.5, 4, 4.5, or 5 were given to grafts where
the respective average numbers of immunoreactive
cells/field of view, using a primary magnification of
20x were 0-2, 3-7, 8-12, 13-17, 18-22, 23-27,
28-32, 33-37, 38-42, 43-47, and > 48. When in
addition to cells, immunoreactive glial or fibrous
processes or both were also noted, the scores were
incremented by 0.5, 1, or 2 for small, moderate, or
large amounts of MHC-I or MHC-II-positive
material. Scores ofOX-42 (CD 1 lb) and ED- 1 were
0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, or 5 given to
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gras where these elements were found in 0-4, 5-
14, 15-24, 25-34, 35-44, 45-54, 55-64, 65-74,
75-84, 85-94, or >95% of the area of the graft
/40/. In addition, the TH-positive volume was
estimated by scoring the percentage of the TH-
positive area at three different levels of the
transplant and then calculating the averages. We
used the Mann-Whitney U test to determine the
differences between paired groups.
RESULTS
Effect of growth factors on graft growth
Figure la shows the growth of intraocular
substantia nigra gratis treated with different
neurotrophic factors. GDNF treatment led to
significantly larger graft volumes than CC (p<0.05).
Figure lb shows the volume of TH-positive regions.
GDNF-treated grafts had a significantly larger TH-
positive volume compared with NT-3 and CC
(p<0.05). Neither BDNF nor NT’3 had a significant
effect on either graft growth or volume of TH-
positive areas in the grafts.
Overall immune response to growth factors
Figures 2-4 summarize the total immunological
score and scores for each immune element.
Although BDNF-treated allografts contained
somewhat larger mean numbers of immune-related
cells, including lymphocytes and antigen-presenting
cells (Figs. 5,8b), the differences were not
significant when compared with the control group
(Figs. 2-4). Occasionally, NT-3 and BDNF
treatments led to higher amounts of immune-related
elements (Figs. 6,8c). GDNF treatment did not
appear to cause any significant immune reactivity.
All transplants contained very low numbers of OX-
38-positive elements (data not shown).
Immunologic patterns for individual growth factors
GDNF-treated transplants showed excellent
neuronal survival (Figs. 7,8). MHC Class I-positive,
ramified microglial cells could be identified, but only
a few such cells were seen in the gratis. In addition,
GDNF-treated gras showed well-developed86 M. SODA ET.
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Fig. 1. a: Growth curves of intraocular transplants given GDNF (triangle) or BDNF (diamond), NT-3 (-El-), and cytochrome-C
(-O-) I Sprague-Dawley rats. GDNF,treated transplants showed increased growth (meand:s.e.m., * p < 0.05) compared
with control, cytochrome-C treatment.
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]ill. 1. b: TH-positive volume in grafts. GDNF treatment led to significantly larger TH-IR areas than BDNF, NT-3, or
cytochrome-C treatment (meand:s.e.m., * p < 0.05).
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Fig. 2. Total immunological scores. BDNF, NT-3, and GDNF treatments causes only minor changes in mean scores. Differences
were not significant.
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Fig. 3. Scores for individual immune markers. Scores ofCD4 were excluded because they were close to zero. The NT-3 treatment
group had a higher meanMHC class II expression score, but the difference was not significant.
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Fig. 4. Microglial alterations. GDNF-treated grafts had well-developed ramified microglial cells and fewer reactive microglial
cells. NT-3-treated grafts had significantly higher numbers of OX-42-positive large and round microglial cells than the
cytochrome-C-treated grafts (p < 0.05).
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Fig. 5. Appearance of a anspla-t. afi.c’ /INI,’ ma.mct (xt0O)o l’hi; particular Iransplanl has an above-average number of
immmmrcac/ive cells (a)’i’ll, (b) (1)g 0:) Mill; (()N.,.tS), (d) MIi/’, II (()X...6), (c) CDIIb (()X.-42), and (f) EDI-I.
Itighcr numbers of immmmcyc4 c;m l}c cc wi/h ()X-.g an|Jbodics, and OX.42-posilivc large and round microglial cells
arc, scc h ar:a ofra-spla ;1to: .}c iH,;o ’:1 .,I..posi/ivc rcac|ivc microglia arc also prcscnL
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that showed severe immune reaclivily after ’-3 trcalmcn ( 106). (a)
(()X,6) (c) CDllb (OX.-42) and (0 EDI-I. Sone T/l.-posifiw muron
;lass II-xpressing cells (especially pcrivascular lesions) 1).,I ,,positiv,
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Fig. 7o Typical appearance of transplants after GDNF trcatnent ( 106). (a) TH, (b) CD8, (c) MHC I (OX-18), (d) MHC II (OX..
6), (e) CD1 lb (OX-42), and (f) EDI-I. Many TH-positive neurons can be seen in the grafts and quite a few immune-
(:la|.cd lnnl. xccpt MI-|C class I-posilivc microglia. OX-42 labeling shows only ramified microglial cells.
V()i,UMI, 6 N(). 2 199’192 M. SItlNODA ET AL.
Fig. 8. Morphologic differences seen with OX-42 antibodies. (a) Close-up view of Fig. 5e. GDNF-treated, well-defined ramified
microglial cells in the grafts. (b) Close-up view of Fig. 6e. BDNF-treated, partly activated (large and round) microglial
elements. (c) Close-up view of Fig. 7e. NT-3-treated severe immunocompromised grafts showing large and round OX-42-
positive cells in a wide area.
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OX-42-positive ramified microglial cells and a few
large, round microglial cells. In addition, GDNF-
treated grafts contained a few microglial reactive
ED-l-positive microglial cells (Figs. 4b, 4c).
Overall, more immunologically com-promised
transplants were found in BDNF-treated (3 of 11)
and in NT-3-treated groups (5 of 14) than in CC-
treated (2 of 17) and GDNF-treated groups (3 of
17). Moreover, grafts with a marked infiltration of
immune cells were found only in the BDNF- (1) and
NT-3-treated (3) groups.
DISCUSSION
The combined data from this and other studies
performed in our laboratories demonstrate that
although treatment with GDNF and to some degree
with BDNF can enhance immune responses to such
immunogenic tissue as fetal spinal cord grafts, the
trophic factors per se do not elicit a significant
response in non-immunogenic grafs like substantia
nigra. In the present study, although GDNF
treatment led to significantly larger substantia nigra
graft volumes than CC treatment, both GDNF and
CC showed almost the same level of immune
reactivity, except for MHC class I positive
elements. GDNF-treated grafts also had the highest
values of normal ramified microglial distribution, as
well as lower numbers of immunoreactive microglial
components and OX-42 positive round and large
microglial cells.
The origin of microglial cells is controversial
/20,35/42/, although most studies have suggested a
mesodermal origin /7,25,27,33/. Three types of
microglial cells are found in the CNS. Ramified
microglia, prominent in the mature CNS, are
derived from ameboid microglia, which, in turn, are
present during late prenatal and early post-natal
ages. Reactive microglia appear primarily in cases
of CNS injury (reviewed in /19,27,33,45/). After
6-OHDA-induced dopaminergic denervation,
microglial cells in substantia nigra have been shown
to express MHC loci /1/, and ED1 and OX-42-
positive microglial cells have also been found in the
substantia nigra area (Shinoda, Lindqvist, and
Olson, unpublished).
As mentioned before, GDNF belongs to the
TGF-13 superfamily /24/ of immunomodulators.
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TGF-13 is produced by a large number of different
cell types, including various cells of the immune
system, such as macrophages, peritoneal monocytes
and neutrophils, as well as by T- and B-
lymphocytes. In cases of injury (localized
inflammation), platelet aggregation and degran-
ulation, one of the earliest events in the
inflammatory response, might occur and trigger the
release of TGFI3. Activated macrophages release
TGF-13 and other cytokines (for example,
intedeukin-1 (IL-1), tumor necrosis factor (TNF),
fibroblast growth factor (FGF), and platelet-derived
growth factor (PDGF). The inhibition of T-cell
proliferation by TGF-13 may reduce the
inflammatory response while promoting healing
/51/. Interestingly, TGF-131 null/deficient mice show
increased M/-/C Classes I and II gene expression
/12/, as well as an increased inflammatory-cell
infiltration of cardiac tissue that is related to
allogeneic cardiac tissue rejection/53/.
We previously reported that in the Sprague-
Dawley strain of rats, GDNF-treated intraocular
allogeneic spinal cord grafts showed the highest
cytotoxic immune responses when compared with
BDNF- and CC-treated grafts. In contrast, we saw
no immune upregulation after GDNF treatment in
syngeneic Fisher strain spinal cord grafts /40/.
Comparing fetal spinal cord grafts /40/ with the
embryonic substantial nigra grafts to the eye
chamber reported here reveals that the immune
reactions elicited by spinal cord tissue tends to be
more pronounced than those induced by ventral
mesencephalic tissue. Two major reasons could
account for the neuroimmunologic differences
between cerebral gray matter and the spinal cord in
development. First, normal mature spinal cord
contains MHC Class I positive microglial cells/22/.
Additionally, in P1 rats MHC Class I-positive
microglial cells can be found on the surface of
cervical and thoracic spinal cord, and they increase
in number and appear to move into the white matter
with time so that several weeks after birth, they
become normal MHC Class I-positive microglial
cells (Shinoda, Kobayashi, and Olson, unpublished).
Substantia nigra, however, does not contain MHC
Class I-positive microglia (Shinoda, Kobayashi, and
Olson, unpublished). Second, the spinal cord also
contains a large proportion of white matter, which
contains more ameboid microglial cells during94 M. SHINODA ET AL.
development/16/. Because they can express MHC
loci and II-1 /13,26/, ameboid and/or activated
microglial cells may contain more immuno-
modulatory components.
Stromberg et al. /44/reported using the same
procedures, in which 0.1, 1 gtg, and 1 mg/eye
GDNF were given to stimulate neuronal growth. In
the present study, the final sizes of GDNF-treated
substantia nigra transplants were more than 1.5-fold
larger than those in Stromberg’s experiments. The
reasons for such differences are as follows: (a) We
used 8 injections of GDNF at 5-day intervals, and
the final period was 42 days after the first injection,
whereas in the former experiments the final period
was only 33 days.
Nerve growth factor (NGF) and other
neurotrophins have been shown to produce several
immunomodulatory effects, such as in mast cells
/2,3,32/, B-cell stimulation /31,43,46/ and
T-lymphocyte stimulation/47/. In the present study,
NT-3, which had no effect on graft growth, elicited
small immunomodulatory effects, particularly
microglial activation. The significantly increased
numbers of OXo42-positive large and round cells in
NT-3-treated transplants suggests that NTo3
stimulates macrophage-related cytotoxic immunity
in neuronal cells. NTo3 and NT-4 mRNA, as well as
truncated trkB and trkC transcripts, have been
found in rat thymus, thymic stroma (tissue depleted
of mononuclear cells), spleen, and splenic stroma
/23/. Concanavalin A-treated rat-thymus cells and
lipopolysaccharide-treated rat-spleen mononuclear
cells express a two-fold increase in NT-4 but not in
NTo3 or BDNF. We have previously shown that
BDNF has almost no immunomodulatory effect on
fetal spinal cord grafts in oculo/40/. Thus it appears
that BDNF does not elicit a strong immunoreaction
in vivo.
In conclusion, neither GDNF nor BDNF
enhanced immune reactivity in allogeneic embryonic
substantia nigra grafts. GDNF may act to
upregulate immune markers in allogeneic CNS
tissue grats where MHC Class I is strongly
expressed, such as in spinal cord, but not in
allogeneic CNS tissue in which MHC Class I is
weakly expressed, such as in substantia nigra.
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